Gene Therapy Trial for CLN6 Batten Disease
Part of paid clinical trials in La Jolla, California.
- Sponsor
- The Charlotte and Gwenyth Gray Foundation
- Study ID
- NCT07582484
- Phase
- PHASE1/PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Batten Disease
- Batten's Disease
- CLN6
- Neuronal Ceroid Lipofuscinosis
- Neuronal Ceroid Lipofuscinosis CLN6
Eligibility Criteria
- Sex
- ALL
- Age
- 4 Months - N/A
- Healthy Volunteers
- Not accepted
Interventions
- scAAV9.CB.CLN6 (dose: 1.5E14 vector genomes) — DRUGself-complementary adeno-associated viral vector, serotype 9 (scAAV9), which contains the human CLN6 gene under the control of a hybrid CMV/CB promoter
Study Details
The goal of this clinical trial is to learn if a gene therapy called scAAV9.CB.CLN6 can treat children with CLN6 Batten disease (variant late infantile neuronal ceroid lipofuscinosis). The main questions it aims to answer are if he gene therapy safe and well tolerated, and if the gene therapy help slow disease progression or improve symptoms. Participants will: Receive a single dose of the gene therapy through an injection into the fluid around the spinal cord (intrathecal administration) Have regular study visits over 2 years for safety checks and assessments of disease progression Be followed for an additional 3 years in a long-term follow-up study
Key Dates
- Start date
- Aug 31, 2026
- Status verified
- May 2026
- Primary completion
- Aug 31, 2027
- Completion
- Aug 31, 2028
Study Design
- Enrollment
- 12 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment group
Primary Outcome Measure
Number of Participants With Treatment-Emergent Adverse Events as Assessed by CTCAE Version 5.0 [ Time Frame: From informed consent through Month 24 ]
Central Contacts
- Tiffany M Sepp617-710-0770
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, San Diego - Rady Children's | La Jolla | California | 92093 |
Find similar trials in La Jolla, CA
Related Studies
- Clinical and Neuropsychological Investigations in Batten DiseaseRecruiting · University of Rochester · Rochester, New York
- UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like CellsPHASE1 · Recruiting · Joanne Kurtzberg, MD · Durham, North Carolina
- Inherited Retinal Degenerative Disease RegistryRecruiting · Foundation Fighting Blindness · Columbia, Maryland
- Investigations of Juvenile Neuronal Ceroid LipofuscinosisRecruiting · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Bethesda, Maryland